How should the immunosuppressive regimen be managed in patients with established chronic allograft failure?
Danovitch
Gabriel M
GM
Division of Nephrology, UCLA School of Medicine, USA. gdanovitch@mednet.ucla.edu
D065095:Calcineurin Inhibitors; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000209:etiology*; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus